Biomarker Discovery in Two Daily Disposable Contact Lenses
NCT ID: NCT03440242
Last Updated: 2018-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
43 participants
OBSERVATIONAL
2018-01-09
2018-10-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Objective Vision Evaluation of Two Cosmetic Contact Lenses
NCT04287036
2-week Evaluation of Marketed Silicone Hydrogel Contact Lenses in Indian Population
NCT02394808
Comparison of a Silicone Hydrogel Daily Disposable Multifocal Contact Lens to a Marketed Product
NCT05258149
Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses
NCT02595502
One Month Daily Wear Clinical Evaluation of New Prototype Contact Lenses in Habitual and Neophyte Contact Lens Wearers
NCT02081677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JJVC Contact Lens (Asymptomatic)
Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
JJVC Contact Lens
etafilcon A with PVP DD
JJVC Contact Lens (Symptomatic)
Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
JJVC Contact Lens
etafilcon A with PVP DD
Marketed Contact Lens (Asymptomatic)
Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
Marketed Contact Lens
nelfilcon A DD
Marketed Contact Lens (Symptomatic)
Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
Marketed Contact Lens
nelfilcon A DD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JJVC Contact Lens
etafilcon A with PVP DD
Marketed Contact Lens
nelfilcon A DD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Appear able and willing to adhere to a no lens wear period of at least one month.
4. Between 18 and 45 (inclusive) years of age at the time of screening.
5. Subject must be currently wearing one of the two habitual contact lenses in both eyes (1DAM or DACP) for at least three months. Habitual CL wear is defined as having a minimum wearing time of 3 hours per day, minimum of 3 days per week for at least 3 months.
6. Subject must have visual acuity of at least 20/40 or better in each eye with their habitual lenses
7. Subjects must meet one of the following criteria in order to be classified as either asymptomatic or symptomatic group:
1. Asymptomatic group: CLDEQ-8 score of ≤7, difference between CWT and AWT \<1 hours/day
2. Symptomatic group: CLDEQ-8 score of ≥15, difference between CWT and AWT \>3 hours/day
8. Have healthy eyes with no evidence of abnormality or disease (i.e., no active ocular pathological conditions/ infections of any type).
9. Have a pair of spectacles that provide corrected binocular visual acuity of 20/40 or better. If no spectacles, subjects must have un-aided binocular visual acuity of 20/40 or better.
Exclusion Criteria
1. Currently pregnant or lactating
2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
3. Unacceptable lens fit with their habitual lenses in either eye based on study investigators judgment.
4. Any extended wear modality.
5. Use of systemic medications (e.g., chronic steroid use, immuno-suppressants or anti-infective medications) that are known to interfere with contact lens wear.
6. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
7. Any previous, or planned (during the course of the study) intraocular/refractive surgery.
8. Any Grade 3 or 4 slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, and conjunctival injection) on the FDA scale.
9. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear.
10. Participation in any interventional contact lens, eye drop or lens care product clinical trial within 30 days prior to study enrollment.
11. Suspicion of or recent history of alcohol or substance abuse, serious mental illness, or seizures.
12. Employee of clinical site (e.g., Investigator, Coordinator, Technician).
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Narayana Nethralaya Foundation
Bangalore, , India
Medical Research Foundation
Chennai, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-5982
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.